The SH2 domain-containing cytoplasmic protein tyrosine phosphatase, SHP-1, negatively regulates hematopoietic cell signaling. SHP-1 is associated with a tyrosine phosphorylated, plasma membrane-spanning glycoprotein, pp130, in colony stimulating factor-1 stimulated or unstimulated macrophages. This association is phosphotyrosine dependent and is mediated by the amino-terminal SH2 domain of SHP-1. pp130 behaves as a substrate of SHP-1 in vitro and is hyperphosphorylated on tyrosine in SHP-1 de®cient macrophages from viable-motheaten mice. Co-immunoprecipitation data indicate that pp130 is the product of the mouse p91/PIR-B gene that encodes a member of the killer cell inhibitory receptor (KIR)/leukocyte immunoglobulin-like receptor (LIR) family. By analogy to the KIRs, p91/ PIR-B may represent a novel class of macrophage receptors which act to suppress macrophage activation. These observations identify SHP-1 interactions with and regulation of p91/PIR-B as a potential mechanism for inhibiting the signaling cascades linking extracellular stimuli to macrophage activation and/or development.
Introduction
Colony stimulating factor-1 (CSF-1) is the primary regulator of macrophage survival, proliferation, and dierentiation in vivo. CSF-1 mediates these eects by binding to the CSF-1 receptor (CSF-1R), a receptor protein tyrosine kinase (RPTK), encoded by the c-fms proto-oncogene. CSF-1 stimulation of macrophages leads to rapid receptor dimerization and autophosphorylation, followed by a transient increase in the tyrosine phosphorylation of both cytosolic and membrane proteins (reviewed in Stanley, 1994) , including the protein tyrosine phosphatase, SHP-1 (Yeung et al., 1992) .
SHP-1 and SHP-2 are members of a family of cytoplasmic SH2-domain-containing protein tyrosine phosphatases (PTPs). In contrast to the ubiquitous distribution and positive downstream regulatory role of SHP-2, the expression of SHP-1 is primarily restricted to hematopoietic and epithelial cells and SHP-1 appears to play key roles in the negative regulation of many growth-promoting signaling cascades by virtue of its association with activated RPTKs, cytokine receptors, the interferon-a receptor, and non-receptor tyrosine kinases, including members of the Janus and Src families of tyrosine kinases (reviewed in Neel and Tonks, 1997) . SHP-1 also negatively regulates B-cell antigen receptor signaling by associating with the B cell antigen receptor and with the immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the cytoplasmic domains of the FcgRII BI and the B-cell antigen co-receptors, CD22 and CD72 (reviewed in Siminovitch and Neel, 1998) . More recently, SHP-1 has been shown to inhibit T-cell activation and to suppress natural killer cell function by associating with the ITIMs of human killer inhibitory receptors (KIRs) or the murine LY49 receptors (reviewed in Unkeless and Jin, 1997) . SHP-1 also associates with a leukocyte immunoglobulin-like receptor-1 (LIR-1) that is expressed in monocytic and B-lymphoid cells (Cosman et al., 1998) as well as a leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) expressed in human mononuclear leukocytes (Meyaard et al., 1997) .
Many of these insights into SHP-1 function have been derived by analysis of motheaten (me/me) and viable-motheaten (me v /me v ) mice that possess inactivating mutations in the gene encoding SHP-1 (reviewed in Bignon and Siminovitch, 1994) . These mice exhibit increased numbers of erythropoietic precursor cells, granulocytes, macrophages, and CD5-positive B-cells, and die prematurely of hemorrhagic pneumonitis, consequent to massive in®ltration of granulocytes and macrophages in the lungs (Bignon and Siminovitch, 1994) . The observation that anti-CD11b antibody prevents the immunopathologic changes in me v /me v mice (Koo et al., 1993) , coupled with the ®nding that B and T cells are not required for the me v /me v phenotype (Yu et al., 1996) , suggests that macrophages play a critical role in the severe in¯ammatory disease manifested by these mice.
Analysis of bone marrow-derived macrophages from me/me and wild-type mice has suggested that SHP-1 negatively regulates CSF-1-induced tyrosine phosphorylation and cell proliferation and revealed the constitutive association of SHP-1 with an unidenti®ed 130 kDa phosphotyrosyl protein (pp130) (Chen et al., 1996) . In the present study, we show that the macrophage pp130 is a membrane-spanning glycoprotein and the product of the recently cloned mouse KIR/LIR family member, p91/PIR-B. Our data identify p91/PIR-B as an SHP-1 substrate in macrophages and suggest that SHP-1 modulatory eects on macrophage activation are realized at least in part through the dephosphorylation of p91/PIR-B.
Results

SHP-1 tyrosine phosphorylation and association with pp130
To investigate the role of SHP-1 in regulating macrophage functions, the pro®le of SHP-1 binding phosphoproteins in CSF-1-treated BAC1.2F5 macrophages was examined by anti-phosphotyrosine (anti-PY) immuno-blotting analysis of SHP-1 immunoprecipitates from BAC1.2F5 cell lysates. As shown in Figure  1 , CSF-1 stimulation induced transient tyrosine phosphorylation of SHP-1 when cells were stimulated for short times at 378C and a higher level of tyrosine phosphorylation when cells were stimulated for 2 h at 48C. Stimulation of cells at 48C has previously been shown to result in higher levels of protein tyrosine phosphorylation, presumably due to dierential inhibition of protein tyrosine phosphatases, compared with kinases under the conditions used (Li, et al., 1991) . Under both temperature conditions, a phosphoprotein species of *130 kDa (pp130) was co-immunoprecipitated with SHP-1 both constitutively and after CSF-1 treatment. While three other phosphoproteins (pp55, pp90 and pp120) were also co-immunoprecipitated with SHP-1 following CSF-1 treatment, the most predominant species associated with SHP-1 in these cells is pp130.
pp130 is a plasma membrane-spanning glycoprotein To determine the subcellular localization of SHP-1 in macrophages, BAC1.2F5 cells were separated into cytosolic, membrane and cytoskeletal fractions, solubilized in SDS ± PAGE sample buer, and subjected to immunoblotting analysis with anti-SHP-1. The results shown in Figure 2A indicate that the vast majority (*95%) of macrophage SHP-1 is localized in the cytosol, while approximately 5% is Figure 1 SHP-1 tyrosine phosphorylation and association with pp130. Cells were incubated with or without CSF-1 for the indicated times at either 378C or 48C. SHP-1 immunoprecipitates from NP-40 cell lysates were subjected to SDS ± PAGE and immunoblot analysis with anti-PY and anti-SHP-1 Figure 2 pp130 is associated with the membrane-localized form of SHP-1. Cells were incubated with (+) or without (7) CSF-1 for 2 h at 48C. (a) Following subcellular fractionation, equivalent portions (corresponding to 2610 6 cells) of cytosolic (C), membrane (M) and cytoskeletal (CSK) fractions were subjected to immunoblot analysis with anti-SHP-1. (b) The cytosolic and solubilized membrane fractions were immunoprecipitated with anti-SHP-1 and subjected to immunoblot analysis as in Figure 1 . To enrich for membrane-localized SHP-1, the membrane fraction used in this experiment is three times the cell equivalent of the cytosolic fraction. The apparent high level of SHP-1 protein in membrane SHP-1 immunoprecipitates is accounted for by the threefold increased membrane concentration and the less complete immunoprecipitation of SHP-1 from the cytosolic fraction. (c) The NP-40 solubilized membrane fraction was subjected to sucrose density gradient zonal centrifugation. Forty fractions were collected, immunoprecipitated with anti-SHP-1 and analysed by SDS ± PAGE and immunoblotting with anti-PY and anti-SHP-1 together with a control SHP-1 immunoprecipitate from unfractionated membrane (C). The positions of the marker proteins bovine serum albumin (BSA, 66 kDa) and catalase (230 kDa) are indicated found in the membrane fraction. To determine which subcellular fraction of SHP-1 associates with pp130, SHP-1 immunoprecipitates of the cytosolic and membrane fractions of unstimulated and CSF-1-stimulated macrophages were subjected to anti-PY immunoblotting analysis ( Figure 2B ). The vast majority of tyrosine phosphorylated SHP-1 was recovered in the cytosolic fraction whereas pp130 and the other SHP-1 associated tyrosine phosphorylated proteins were exclusively recovered in the membrane fraction. Consistent with the results shown in Figure 1 , pp130 tyrosine phosphorylation and/or association with membrane-localized SHP-1 appeared to be unaltered in response to CSF-1, although we noted a small but reproduceable increase in the amount of SHP-1 localized to the membrane fraction following CSF-1 treatment (also depicted in Figure  2A ). To demonstrate that SHP-1 and pp130 exist in a complex in vivo, the membrane fraction was subjected to zonal centrifugation in a sucrose density gradient, and individual fractions immunoprecipitated with anti-SHP-1 and separately monitored for pp130 and SHP-1 by immunoblotting with anti-PY and anti-SHP-1 respectively. As illustrated in Figure 2C , although a small portion of membrane SHP-1 co-sedimented with the 66 kDa BSA marker, the majority of SHP-1 cosedimented in faster sedimenting fractions that contained pp130. This result indicates that pp130 is physically associated with SHP-1, and furthermore, that almost all of the membrane-bound SHP-1 is in a complex with pp130.
To determine whether pp130 is a glycoprotein, solubilized membrane lysates from macrophages were depleted of glycoproteins by passage through a wheat germ agglutinin column and the¯ow-through fractions then subjected to anti-SHP-1 or anti-CSF-1R (positive control) immunoprecipitation and anti-PY immunoblotting analysis ( Figure 3A ). The absence of pp130 in the¯ow-through fractions indicated that pp130 contains N-acetylglucosamine or sialic acid. As expected ( Figure 2B ), all of the tyrosine phosphorylated SHP-1 was recovered from the supernatant of wheat germ agglutinin-treated lysates. To formally demonstrate that pp130 is a plasma membrane-spanning protein possessing an extracellular domain, intact macrophages were surface-labeled with 125 I, lysed, and the lysates then subjected to anti-SHP-1 and anti-CSF-1R (positive control) immunoprecipitation and autoradiography. As shown in Figure 3B these data revealed the presence of a single radioiodinated band corresponding to pp130 in the SHP-1 immunoprecipitates, demonstrating that pp130 represents a plasma membrane-spanning glycoprotein.
The amino-terminal SH2 domain of SHP-1 mediates pp130 binding
To investigate the basis for SHP-1 binding to pp130, the eects of phosphotyrosine or a phosphotyrosine analog on this interaction were studied. As shown in Figure 4A , in the presence of exogenous phosphotyrosine or phenylphosphate, the SHP-1/pp130 complex was completely dissociated. Thus this association appears to be mediated by binding of pp130 phosphotyrosine residues with the SHP-1 SH2 domains. To determine whether either or both SHP-1 SH2 domains were sucient for binding, GST ± SH2 domain fusion proteins bound to glutathione agarose beads were incubated with NP-40 BAC1.2F5 cell lysates and the capacity of the GST ± SH2 domains to bind pp130 assessed by anti-PY immunoblotting analysis. As shown in Figure 4B , this analysis revealed the capacity of the tandem SH2 domain and aminoterminal SH2 domain fusion proteins, but not the carboxyl-terminal SH2 domain proteins to bind pp130. Furthermore, pp130 was the only tyrosine phosphorylated protein from BAC1.2F5 cells which was consistently bound by these SH2 domain fusion proteins. These observations suggest that it is the SHP-1 amino-terminal SH2 domain which mediates SHP-1 binding to pp130.
pp130 is an in vitro and in vivo substrate of SHP-1
In vitro binding experiments utilizing the full-length wild-type SHP-1 and the catalytically inactive C453S SHP-1 indicated that the C453S SHP-1 bound more pp130 than the wild-type SHP-1 ( Figure 4B ). This observation suggests that pp130 is an SHP-1 substrate, a possibility that was directly examined by analysis of the capacity of SHP-1 to dephosphorylate pp130 in vitro. SHP-1 immunoprecipitates of solubilized membrane fractions from BAC1.2F5 macrophages were incubated at 208C and samples taken at various times were analysed by anti-PY immunoblotting. As illustrated in Figure 5A , this analysis revealed a marked reduction in the intensity of the pp130 band with time. The possibility that non-speci®c precipitation of an unrelated PTP might account for this result was ruled out by the demonstration that anti-SHP-1 immunoprecipitates from me/me macrophages lacked detectable PTP activity when assayed with a 32 P-labeled poly-glutyr substrate, while substantial PTP activity was detected in anti-SHP-1 immunoprecipitates from wildtype cells (data not shown). To investigate the I and washed ®ve times with PBS. Anti-SHP-1 or anti-CSF-1R immunoprecipitates of NP-40 cell lysates were analysed by SDS ± PAGE and autoradiography physiological signi®cance of these ®ndings, the phosphorylation status of pp130 was next studied using bone-marrow-derived macrophages from me v / me v mice, animals which express a catalytically inert form of SHP-1 (Kozlowski et al., 1993) . As indicated by the anti-PY immunoblotting analysis shown in Figure 5B , the intensity of the pp130 band coimmunoprecipitated with SHP-1 from me v /me v macrophages was substantially greater than that detected in wild-type macrophages. Together, these observations suggest that pp130 represents a substrate for SHP-1 in vivo and as such is relevant to the function of SHP-1 in macrophages. In addition, the increased tyrosine phosphorylation of the altered forms of SHP-1 present in me v /me v macrophages ( Figure 5B ) indicate that SHP-1 normally modulates its own state of tyrosine phosphorylation in vivo.
pp130 is the product of the p91/PIR-B gene SHP-1 has been shown to associate with the *130 kDa stem cell factor receptor and with the *130 kDa interleukin-3 receptor b subunit in vivo (reviewed in Neel and Tonks, 1997), and with the signal regulatory protein a1 (SIRPa1) in vitro (Kharitonenkov et al., 1997) . The possibility that pp130 represented one of these species was thus explored. However, BAC 1.2F5 cells do not express the stem cell factor receptor and the interleukin-3 receptor b subunit was found to migrate more slowly than pp130 in these cells (data not shown). Similarly, SHP-1 and SIRPa1 were not co-immunoprecipitable from these cells (data not shown).
Another candidate protein of *130 kDa is the recently identi®ed product of the p91 (Hayami et al., (a) NP-40 cell lysates containing the indicated concentrations of phenyl phosphate (PhP) or phosphotyrosine (PY) were subjected to anti-SHP-1 immunoprecipitation. Immunoprecipitated proteins were separated on SDS ± PAGE and immunoblotted with anti-PY and anti-SHP-1. (b) NP-40 cell lysates were incubated with glutathione-agarose beads bound to GST or to GST fused with either the SHP-1 amino-terminal SH2 domain (N-SH2) or the carboxyl-terminal SH2 domain (C-SH2) or both (N+C-SH2) domains or wild-type SHP-1 or the C453S SHP-1. The bound proteins were eluted with SDS sample buer and subjected to immunoblot analysis with anti-PY. Below, the glutathione-agarose beads bound to GST or to the GST fusion proteins were eluted with SDS sample buer and the eluted proteins subjected to SDS ± PAGE and stained with Coomassie blue 1997)/PIR-B (Kubagawa et al., 1997) gene, the cDNA of which we cloned independently. p91/PIR-B represents a membrane-spanning glycoprotein that belongs to the KIR/LIR family and is preferentially expressed in macrophages (Hayami et al., 1997; Kubagawa et al., 1997; Cosman et al., 1998) , however its function has not been established. As illustrated in Figure 6A , antibodies to p91 immunoprecipitated a tyrosine phosphorylated species that co-migrates with the pp130 species coprecipitated with SHP-1. A reprobing of this blot with anti-p91 antiserum demonstrated that p91 co-precipitates with SHP-1 and co-migrates with pp130, indicating that the SHP-1-associated pp130 species contains p91. Furthermore, reprobing of this immunoblot with anti-SHP-1 antibody revealed the presence of SHP-1 in the p91 immunoprecipitates, and con®rmed that only a small portion of total cellular SHP-1 is bound to p91. To establish that p91 is the only 130 kDa species associated with SHP-1 in macrophages, NP-40 BAC1.2F5 lysates were depleted of p91 by three sequential anti-p91 immunoprecipitations. SHP-1 immunoprecipitates of the p91-depleted and control lysates were then examined by immunoblotting analysis using anti-PY, anti-p91 and anti-SHP-1 antibodies. As shown in Figure 6B , depletion of tyrosine phosphorylated pp130 by anti-p91 preclearance was virtually complete and paralleled the depletion of p91 protein.
As expected, the majority of SHP-1 was still recoverable following p91 depletion. These results show that p91 is the only 130 kDa tyrosine phosphorylated protein associated with SHP-1 in these cells. Furthermore, since only a small fraction of total cellular p91 coprecipitates with SHP-1, but the tyrosine phosphorylation of SHP-1-associated p91 appears comparable to that of total precipitable p91 ( Figure 6A ), it appears likely that SHP-1 selectively associates with the tyrosine phosphorylated form of p91.
Discussion
The data reported here demonstrate that the major tyrosine phosphorylated protein associated with SHP-1 in macrophages is p91/PIR-B. p91 is a member of a family of immune system inhibitory receptors that includes the KIRs, gp49, leukocyte immunoglobulinlike receptor-1 (LIR-1), leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1), immunoglobulinlike transcripts (ILT1, ILT3, ILT4, ILT5 and ILT2/ LIR-1), and the monocyte immunoglobulin-like receptors (MIRs) (reviewed in Yokoyama, 1997) . Each of these receptors contains extracellular Ig-like domains, a transmembrane domain and a cytoplasmic domain containing ITIM sequences. The ligands for many of these receptors are unknown. However, the ®nding that KIRs bind MHC class I antigens resulting in inhibition of natural killer cell cytolysis of cells expressing`self' antigens, suggests that these receptors may be involved in a common mechanism by which dierent cells in the immune system respond appropriately to`self' antigens (Yokoyama, 1997) . ITIMs may mediate the inhibitory eects of these receptors by recruiting PTPs that suppress tyrosine phosphorylation in signal transduction cascades that activate cellular functions. Indeed, the KIRs, gp49, LIR-1 and LAIR-1 have been shown to recruit SHP-1 upon ligation and/or tyrosine phosphorylation, and in two cases, the ITIM domains have been shown to mediate SHP-1 association (Cosman et al., 1998; Meyaard et al., 1997; Kuroiwa et al., 1998; Burshtyn et al., 1996) . p91/PIR-B is preferentially expressed in macrophages and is comprised of ®ve or six extracellular Ig domains, a transmembrane domain and four ITIM or ITIM-like domains (Hayami et al., 1997; Kubagawa et al., 1997) . There is a high degree of sequence similarity between p91 and the human KIRs, the human MIRs, human LIR-1, and murine gp49B (Hayami et al., 1997; Cosman et al., 1998; Wagtmann et al., 1997) . p91 also exhibits high sequence similarity with the human Fca receptor and the bovine Fcg2 receptor; however, as it does not bind the Fc portion of Ig, it does not appear to function as an Fc receptor (Hayami et al., 1997) . Of particular interest is its similarity to LIR-1 and the MIRs, which both possess four ITIM domains and are predominantly expressed on monocytic and B lymphoid cells. LIR-1 speci®cally interacts with class I MHC molecules and binds SHP-1 in a tyrosine phosphorylation dependent manner (Cosman et al., 1998) . The association of MHC class I molecules is likely to lead to LIR-1 tyrosine phosphorylation and the recruitment and activation of SHP-1 to negatively regulate monocytic/B cell signaling pathways (Cosman et al., 1998) . However, the ligand for p91 has not been reported and it is unclear whether p91 represents the mouse homolog of either the MIRs or LIR-1.
The data reported here indicate that the interaction between SHP-1 and p91/PIR-B in the macrophage appears to be mediated through the binding of tyrosine phosphorylated residues on p91/PIR-B with the aminoterminal SH2 domain of SHP-1. This ®nding implies that the p91-associated SHP-1 is therefore in an active conformation since phosphopeptide binding by the amino-terminal SH2 domains of both SHP-1 (Pei et al., 1996) and SHP-2 (Hof et al., 1998) has been demonstrated to activate these phosphatases. As the Figure 6 pp130 is the product of the p91/PIR-B gene. (a) BAC1.2F5 macrophages were incubated with (+) or without (7) CSF-1 for 1 min at 378C. Anti-SHP-1 or anti-p91 immunoprecipitates of NP-40 cell lysates were subjected to SDS ± PAGE and immunoblotting with anti-PY, anti-p91 and anti-SHP-1. (b) Anti-SHP-1 immunoprecipitated from BAC1.2F5 cell lysates before (lane 1) and after (lane 2) anti-p91 preclearance were subjected to SDS ± PAGE and immunoblotting with anti-PY, anti-p91, and anti-SHP-1 intracellular region of p91/PIR-B contains a number of ITIM motifs, it appears likely that SHP-1 binding to p91/PIR-B involves phosphorylated tyrosine residues within these motifs. Interestingly, this interaction occurs constitutively, and while maintained following CSF-1 treatment, is not signi®cantly upregulated by activation of the CSF-1R (Figures 1; 5 ; 6). Our ®nding that p91 is constitutively tyrosine phosphorylated in macrophages, coupled with our data indicating that p91 is a physiological substrate of SHP-1, suggest that p91 may be partially activated in cultured macrophages, either by ligands present in the culture medium or produced by the macrophages themselves. However, since the ligand for p91 is unknown, the reason for the high level of p91 tyrosine phosphorylation in resting macrophages is unclear.
The current data identifying p91 as a major SHP-1-binding protein and substrate in macrophages suggest that SHP-1 modulation of p91 function plays a signi®cant role in regulating macrophage behavior. This contention is supported by the enormous expansion of macrophage/monocyte populations found in SHP-1-de®cient me/me and me v /me v mice and the demonstration that p91 is hyperphosphorylated in me v /me v macrophages. In contrast to a previous report (Chen, et al., 1996) we have reproducably shown that there is no dierence in the CSF-1-induced proliferation rate between wild-type and me/me or me v /me v macrophages (unpublished observations). As p91 phosphorylation is not signi®cantly in¯uenced by CSF-1 stimulation ( Figure  6 ) and CSF-1-induced macrophage proliferation is not aected by the absence of SHP-1, it appears that the impact of SHP-1/p91 interactions on macrophage biology do not include the modulation of CSF-1 receptor-evoked proliferation. Thus, it is currently unclear whether the eect of the SHP-1-p91 interaction on macrophage behavior is realized through modulation of signaling cascades directly downstream of p91 or through co-modulation of other receptors which in¯uence macrophage function, activation or development. However, the current data identifying p91 as a major target for SHP-1 modulation in macrophages together with the enormous macrophage expansion and activation observed in SHP-1-de®cient mice identify SHP-1 regulation of p91 as a key component of the signaling cascades potentially regulating many facets of macrophage physiology.
Materials and methods
Cell culture and manipulation
Femoral and tibial bone marrow-derived macrophages were obtained from 2 ± 3 week old me v /me v and wild-type litter-mate control mice as described (Stanley, 1990) . Primary and BAC1.2F5 cell line macrophages were maintained in alpha medium containing 15% fetal calf serum (primary cells) or 10% newborn calf serum (BAC1.2F5 cells) with 36 ng/ml CSF-1 (a gift from Chiron Corp. (Emeryville, CA, USA)) (Stanley, 1990) . Upregulation and stimulation of cells with 12 mg/ml CSF-1 at 48C or 378C, their solubilization with Nonidet P-40 (NP-40), and their subcellular fractionation were performed as described previously (Li et al., 1991; Wang et al., 1996) . For sucrose density gradient zonal centrifugation, a highly concentrated NP-40 solubilized membrane extract was prepared and layered onto a gradient of 10 ± 30% sucrose in NP-40 lysis buer. Following centrifugation (18 h, 180 000 g in an SW41Ti rotor (Beckman, Palo Alto, CA, USA), 40 fractions of 0.6 ml were collected and subjected to immunoprecipitation with anti-SHP-1 antibody as described below. For cell surface labeling, adherent macrophages were labeled with 125 I (Amersham, Arlington Heights, IL, USA) using lactoperoxidase (Calbiochem, La Jolla, CA, USA) and glucose oxidase (Sigma, St Louis, MO, USA) (Hubbard and Cohn, 1975) , washed extensively with ice-cold PBS, and solubilized as described above.
Immunoprecipitation and Western blotting
A rabbit antiserum directed against a unique carboxyterminal peptide of SHP-1 (KREEKVKKQRSADK-EKS) (Yeung et al., 1992) was used for immunoprecipitation (1/ 50 dilution) and immunoblotting (1/300 dilution). Anti-CSF-1R antibodies to COOH-terminal and interkinase domain peptides (BuÈ scher et al., 1993) were used for Western blotting and immunoprecipitation. To prepare the anti-p91 antiserum, the cytoplasmic domain of p91 (containing amino acids 675 ± 840) was cut out of a VP16 vector with BamHI and EcoRI and cloned into the BamHI and EcoRI sites of pGex-3X (Pharmacia, Biotech Inc., Piscataway, NJ, USA). The GST-p91 fusion protein was anity puri®ed from E. coli BL21 lysates using glutathione-agarose beads. A New Zealand White rabbit was immunized and boosted with 500 mg of the puri®ed fusion protein and test bleeds titered by immunoblotting of FDC-P1 cell lysates. This antiserum was used for both immunoprecipitation (1/200) and Western blotting (1/ 10 000). In some experiments NP-40 cell lysates were preabsorbed with wheat germ agglutinin (Vector Laboratories, Burlingame, CA, USA), before immunoprecipitation. Immunoprecipitation and immunoblotting with anti-PY were carried out as described . Where indicated, membranes were stripped with buered 1M NaCl and reprobed with anti-SHP-1 or anti-p91 antibody. For immune-complex phosphatase assays, SHP-1 immunoprecipitates from BAC1.2F5 membrane extracts were washed with and resuspended in phosphatase buer (10 mM TrisHCl, pH 7.3, 1.0 mM EDTA, 0.1% 2-mercaptoethanol) and incubated at 208C for the indicated times. The reactions were terminated with SDS sample buer and analysed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS ± PAGE) followed by anti-PY immunoblotting.
In vitro binding assays
Glutathione S-transferase (GST) expression plasmids encoding the amino-terminal SH2 domain, the aminoand carboxyl-terminal SH2 domains of SHP-1, full length wild-type and C453S SHP-1 (Somani et al., 1997) , and the carboxyl-terminal SH2 domain (Yi and Ihle, 1993) were transformed into Escherichia Coli DH5a and the fusion proteins puri®ed from isopropyl-1-thio-b-D-galactopyranoside-induced bacteria with glutathione-conjugated Sepharose beads (Pharmacia Biotech, Inc., Piscataway, NJ, USA). For binding studies, 5 mg of each GST fusion protein immobilized on glutathione beads were incubated with 1 mg of BAC1.2F5 NP-40 cell lysate protein for 2 h at 48C. The beads and bound proteins were washed four times with NP-40 lysis buer, eluted with SDS ± PAGE sample buer, and analysed by SDS ± PAGE and anti-PY immunoblotting.
Abbreviations PTP, protein tyrosine phosphatase; SH2, src homology 2; SHP-1, SH2 domain PTP-1; CSF-1, colony stimulating factor-1; CSF-1R, CSF-1 receptor; RPTK, receptor protein tyrosine kinase; KIR, killer cell inhibitory receptor; LIR-1, leukocyte immunoglobulin-like receptor-1; ITIM, immunoreceptor tyrosine-based inhibitory motif; PBS, phosphate buered saline; NP-40, Nonidet P-40; PY, phosphotyrosine; GST, glutathione S-transferase; SDS ± PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.
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